PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer

PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer

The purpose of the current study is to investigate the prognostic significance of M2 isoform of pyruvate kinase (PKM2) <i>mRNA</i> expression loss in patients with operable colon cancer (CC). Two hundred sixty-two specimens from patients with stage-III or high-risk stage-II CC (group-A)...

Full description

Bibliographic Details
Main Authors: Maria Sfakianaki, Chara Papadaki, Maria Tzardi, Maria Trypaki, Stavroula Manolakou, Ippokratis Messaritakis, Zenia Saridaki, Elias Athanasakis, Dimitrios Mavroudis, John Tsiaoussis, Nikolaos Gouvas, John Souglakos
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Cancers
Subjects:
PKM2
<i>ΚRAS</i>
<i>BRAF</i>
MSI
prediction
colon cancer
Online Access:https://www.mdpi.com/2072-6694/12/8/2058

Internet

https://www.mdpi.com/2072-6694/12/8/2058

Similar Items